PMID- 29264115
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2214-3882 (Print)
IS  - 2214-3890 (Electronic)
IS  - 2214-3882 (Linking)
VI  - 2
IP  - 1
DP  - 2015 Jan
TI  - Renal cell carcinoma: An update for the practicing urologist.
PG  - 19-25
LID - 10.1016/j.ajur.2015.04.012 [doi]
AB  - Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved 
      drastically, with agents targeting vascular endothelial growth factor (VEGF) and 
      the mammalian target of rapamycin (mTOR) now representing a standard of care. The 
      present paper is to review the current status of relevant clinical trials that 
      were either recently completed or ongoing. (1) Though observation remains a 
      standard of care following resection of localized disease, multiple trials are 
      underway to assess VEGF- and mTOR-directed therapies in this setting. (2) While 
      the preponderance of retrospective data favors cytoreductive nephrectomy in the 
      context of targeted agents, prospective data to support this approach is still 
      forthcoming. (3) The first-line management of mRCC may change substantially with 
      multiple studies exploring vaccines, immune checkpoint inhibitors, and novel 
      targeted agents currently underway. In general, prospective studies that will 
      report within the next several years will be critical in defining the role of 
      adjuvant therapy and cytoreductive nephrectomy. Over the same span of time, the 
      current treatment paradigm for first-line therapy may evolve.
FAU - Pal, Sumanta K
AU  - Pal SK
AD  - Department of Medical Oncology & Experimental Therapeutics, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Bergerot, Paulo
AU  - Bergerot P
AD  - Health Department of Federal District (SES) - HRAN, Brasilia, Brazil.
FAU - Figlin, Robert A
AU  - Figlin RA
AD  - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150416
PL  - Singapore
TA  - Asian J Urol
JT  - Asian journal of urology
JID - 101699720
PMC - PMC5730695
OTO - NOTNLM
OT  - Cabozantinib
OT  - Cytoreductive nephrectomy
OT  - Immunotherapy
OT  - PD-1
OT  - Renal cell carcinoma
OT  - Sdjuvant therapy
OT  - Vaccines
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
PMCR- 2015/04/16
CRDT- 2017/12/22 06:00
PHST- 2014/08/02 00:00 [received]
PHST- 2014/08/27 00:00 [revised]
PHST- 2014/09/03 00:00 [accepted]
PHST- 2017/12/22 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PHST- 2015/04/16 00:00 [pmc-release]
AID - S2214-3882(15)00036-3 [pii]
AID - 10.1016/j.ajur.2015.04.012 [doi]
PST - ppublish
SO  - Asian J Urol. 2015 Jan;2(1):19-25. doi: 10.1016/j.ajur.2015.04.012. Epub 2015 Apr 
      16.